A Answers (1)
Onglyza (saxagliptin) is a brand name for the active ingredient saxagliptin. Onglyza is one of the newer medications developed to treat type 2 diabetes mellitus. The current patent for Onglyza will expire in February 2021. If no lawsuits or extensions are applied, it may be available in generic version soon after that date.
Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.